These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 21651357)

  • 1. Inflammatory bowel disease: beyond the boundaries of the bowel.
    Actis GC; Rosina F; Mackay IR
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):401-10. PubMed ID: 21651357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
    Cătană CS; Berindan Neagoe I; Cozma V; Magdaş C; Tăbăran F; Dumitraşcu DL
    World J Gastroenterol; 2015 May; 21(19):5823-30. PubMed ID: 26019446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?
    Reuter BK; Pizarro TT
    Eur J Immunol; 2004 Sep; 34(9):2347-55. PubMed ID: 15307167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease.
    Cantor MJ; Nickerson P; Bernstein CN
    Am J Gastroenterol; 2005 May; 100(5):1134-42. PubMed ID: 15842590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease.
    Abraham C; Cho JH
    Annu Rev Med; 2009; 60():97-110. PubMed ID: 18976050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
    Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
    J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms.
    Balding J; Livingstone WJ; Conroy J; Mynett-Johnson L; Weir DG; Mahmud N; Smith OP
    Mediators Inflamm; 2004 Jun; 13(3):181-7. PubMed ID: 15223609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extraintestinal considerations in inflammatory bowel disease.
    Levine JB; Lukawski-Trubish D
    Gastroenterol Clin North Am; 1995 Sep; 24(3):633-46. PubMed ID: 8809240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
    Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
    Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathogenesis of inflammatory bowel disease: current concepts.
    Bamias G; Cominelli F
    Curr Opin Gastroenterol; 2007 Jul; 23(4):365-9. PubMed ID: 17545770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New mediators of immunity and inflammation in inflammatory bowel disease.
    Monteleone G; Fina D; Caruso R; Pallone F
    Curr Opin Gastroenterol; 2006 Jul; 22(4):361-4. PubMed ID: 16760750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases.
    Sartor RB
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):5S-11S. PubMed ID: 9395346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint involvement associated with inflammatory bowel disease.
    De Vos M
    Dig Dis; 2009; 27(4):511-5. PubMed ID: 19897967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extraintestinal manifestations of inflammatory bowel disease.
    Urlep D; Mamula P; Baldassano R
    Minerva Gastroenterol Dietol; 2005 Jun; 51(2):147-63. PubMed ID: 15990704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells.
    Sasaoka T; Ito M; Yamashita J; Nakajima K; Tanaka I; Narita M; Hara Y; Hada K; Takahashi M; Ohno Y; Matsuo T; Kaneshiro Y; Tanaka H; Kaneko K
    Am J Physiol Gastrointest Liver Physiol; 2011 Apr; 300(4):G568-76. PubMed ID: 21193526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine.
    Goyette P; Labbé C; Trinh TT; Xavier RJ; Rioux JD
    Ann Med; 2007; 39(3):177-99. PubMed ID: 17457716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review.
    Apgar JT
    Semin Dermatol; 1991 Sep; 10(3):138-47. PubMed ID: 1931561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB in inflammatory bowel disease.
    Atreya I; Atreya R; Neurath MF
    J Intern Med; 2008 Jun; 263(6):591-6. PubMed ID: 18479258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.